37 results on '"Etzel J"'
Search Results
2. Das Rezept für Bewegung - ein Instrument zur Unterstützung der ärztlichen Bewegungsberatung
- Author
-
van Geenen, M, Etzel, J, van Geenen, M, and Etzel, J
- Published
- 2023
3. Microbial Decomposition of Pentachlorophenol
- Author
-
Kirsch, Edwin J. and Etzel, J. E.
- Published
- 1973
4. Evaluation of gamma radiation for degradation of a polychlorinated biphenyl in solution and on activated carbon
- Author
-
Schweitzer, J. F., Born, G. S., Etzel, J. E., and Kessler, W. V.
- Published
- 1987
- Full Text
- View/download PDF
5. Laser measuring system for incremental assemblies
- Author
-
Etzel, J. G and Munford, J. A
- Subjects
Lasers And Masers - Abstract
Wire-wrapped frame assemblies used in spark chambers and the like can be measured using a system which utilizes a laser, an interferometer, and a retroreflector to precisely measure distance. A light source and a photodetector are located adjacent the incremental assembly and mounted on a movable carriage. The interferometer is also mounted on the movable carriage, while the laser and retroreflector are positioned at either end of the carriage track. The carriage is moved along one edge of the incremental assembly between the retroreflector and the laser, and as the carriage is moved, the light from the light source to the photodetector is interrupted. This produces a trigger command to a control unit which in turn causes a distance measurement to be made. A printout is provided for each sampling trigger command to list such items as ideal position, actual position and amount of error.
- Published
- 1981
6. Automated inspection of wire-frame assemblies
- Author
-
Etzel, J. G and Munford, J. A
- Subjects
Mechanics - Abstract
System improves accuracy of measurement between spaces of wire mesh and other wire frame assemblies while significantly reducing inspection time. Device operates automatically producing printout of measured spacings through use of optical scanner.
- Published
- 1979
7. Laser measuring system for wire-wrapped frame assemblies
- Author
-
Etzel, J. G and Munford, J. A
- Subjects
Space Radiation - Abstract
The laser measuring system is designed to automatically measure and record the distances between small diameter wires on a wire wrapped grid frame assembly to an accuracy of 0.00635 mm (0.00025 in.). The system utilizes a helium-neon gas laser beam as the measuring instrument with a remote interferometer and retroreflector, a light source and photodetector to detect the wire positions, in conjunction with recording, display and printout units. The laser measuring system is utilized to perform precise automatic measurements for wire application machines or as an automatic feedback device for positioning wires and/or to adjust them for out of tolerance conditions.
- Published
- 1979
8. Weld quality monitor
- Author
-
Etzel, J. G and Mumford, J. A
- Subjects
Machine Elements And Processes - Abstract
Weld quality monitor for production testing of welding strength in electronic circuitry
- Published
- 1969
9. Development of a Weld Quality Monitor
- Author
-
Etzel, J. G and Munford, J. A
- Subjects
Machine Elements And Processes - Abstract
Development of automatic quality control device for measuring welded joints
- Published
- 1969
10. Gage monitors quality of cross-wire resistance welds
- Author
-
Etzel, J and Piltch, A
- Subjects
Electronic Components And Circuits - Abstract
Gage nondestructively monitors the quality of cross-wire resistance welds during the welding operation. The gage gives a dial indication of the relative embedment of the cross wires during the actual welding operation. A direct relationship exists between the depth of embedment and both weld strength and consistency.
- Published
- 1968
11. Human response to α-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: Biphasic influence of dose, age, gender, and receptor genotype
- Author
-
KING, D, primary, ETZEL, J, additional, CHOPRA, S, additional, SMITH, J, additional, CADMAN, P, additional, RAO, F, additional, FUNK, S, additional, RANA, B, additional, SCHORK, N, additional, and INSEL, P, additional
- Published
- 2005
- Full Text
- View/download PDF
12. Genetic variation in the human ?2B-ADRENERGIC receptor gene: Haplotypes and yohimbine response
- Author
-
ETZEL, J, primary, RANA, B, additional, WEN, G, additional, PARMER, R, additional, SCHORK, N, additional, OCONNOR, D, additional, and INSEL, P, additional
- Published
- 2005
- Full Text
- View/download PDF
13. PG15: FACTORS INFLUENCING THE DURATION OF GI MEDICATION TREATMENT ASSOCIATED WITH NSAID-INDUCED GASTROPATHY
- Author
-
Wu, WK, primary, Etzel, J, additional, and McHugh, J, additional
- Published
- 1999
- Full Text
- View/download PDF
14. Evaluation of effects of altered gastric pH on absorption of dapsone in healthy volunteers
- Author
-
Breen, G A, primary, Brocavich, J M, additional, Etzel, J V, additional, Shah, V, additional, Schaefer, P, additional, and Forlenza, S, additional
- Published
- 1994
- Full Text
- View/download PDF
15. Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia
- Author
-
Etzel, J V, primary, Nafziger, A N, additional, and Bertino, J S, additional
- Published
- 1992
- Full Text
- View/download PDF
16. The synthesis and purification of pentachloro-phenol−14C6.
- Author
-
Rogers, R. R., Christia, J. E., Etzel, J. E., and Born, G. S.
- Published
- 1971
- Full Text
- View/download PDF
17. Heavy metals removal by high gradient magnetic separation.
- Author
-
Anand, P., Etzel, J., and Friedlaender, F.
- Published
- 1985
- Full Text
- View/download PDF
18. The synthesis and purification of pentachloro‐phenol−14C6
- Author
-
Rogers, R. R., primary, Christia, J. E., additional, Etzel, J. E., additional, and Born, G. S., additional
- Published
- 1971
- Full Text
- View/download PDF
19. Sewage sludge conditioning and disinfection by gamma irradiation.
- Author
-
Etzel, J E, primary, Born, G S, additional, Stein, J, additional, Helbing, T J, additional, and Baney, G, additional
- Published
- 1969
- Full Text
- View/download PDF
20. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
- Author
-
Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward V Loftus, Elham Ostad-Saffari, Astrid Scalori, Young S Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William J Sandborn, Humberto Aguilar, Tariq Ahmad, Evangelos Akriviadis, Xavier Aldeguer Mante, Istvan Altorjay, Ashwin Ananthakrishnan, Vibeke Andersen, Montserrat Andreu Garcia, Guy Aumais, Irit Avni-Biron, Jeffrey Axler, Kamran Ayub, Filip Baert, Mauro Bafutto, George Bamias, Isaac Bassan, Curtis Baum, Laurent Beaugerie, Brian Behm, Pradeep Bekal, Michael Bennett, Fernando Bermejo San Jose, Charles Bernstein, Dominik Bettenworth, Sudhir Bhaskar, Livia Biancone, Bahri Bilir, Michael Blaeker, Stuart Bloom, Verle Bohman, Francisco Javier Bosques Padilla, Yoram Bouhnik, Gerd Bouma, Raymond Bourdages, Stephan Brand, Brian Bressler, Markus Brückner, Carsten Buening, Franck Carbonnel, Thomas Caves, Jonathon Chapman, Jae Hee Cheon, Naoki Chiba, Camelia Chioncel, Dimitrios Christodoulou, Martin Clodi, Albert Cohen, Gino Roberto Corazza, Richard Corlin, Rocco Cosintino, Fraser Cummings, Robin Dalal, Silvio Danese, Marc De Maeyer, Carlos Fernando De Magalhães Francesconi, Aminda De Silva, Henry Debinski, Pierre Desreumaux, Olivier Dewit, Geert D'Haens, Sandra Di Felice Boratto, John Nik Ding, Tyler Dixon, Gerald Dryden, George Aaron Du Vall, Matthias Ebert, Ana Echarri Piudo, Robert Ehehalt, Magdy Elkhashab, Craig Ennis, Jason Etzel, Jan Fallingborg, Brian Feagan, Roland Fejes, Daniel Ferraz de Campos Mazo, Valéria Ferreira de Almeida Borges, Andreas Fischer, Alan Fixelle, Mark Fleisher, Sharyle Fowler, Bradley Freilich, Keith Friedenberg, Walter Fries, Csaba Fulop, Mathurin Fumery, Sergio Fuster, Gyula G Kiss, Santiago Garcia Lopez, Sonja Gassner, Kanwar Gill, Cyrielle Gilletta de Saint Joseph, Philip Ginsburg, Paolo Gionchetti, Eran Goldin, Adrian-Eugen Goldis, Hector Alejandro Gomez Jaramillo, Maciej Gonciarz, Glenn Gordon, Daniel Green, Jean-Charles Grimaud, Rogelio Guajardo Rodriguez, Zoltan Gurzo, Alexandra Gutierrez, Tibor Gyökeres, Ki Baik Hahm, Stephen Hanauer, John Hanson, William Harlan III, Peter Hasselblatt, Buhussain Hayee, Xavier Hebuterne, Peter Hendy, Melvin Heyman, Peter Higgins, Raouf Hilal, Pieter Hindryckx, Frank Hoentjen, Peter Hoffmann, Frank Holtkamp-Endemann, Gerald Holtmann, Gyula Horvat, Stefanie Howaldt, Samuel Huber, Ikechukwu Ibegbu, Maria Isabel Iborra Colomino, Peter Irving, Kim Isaacs, Kiran Jagarlamudi, Rajesh Jain, Sender Jankiel Miszputen, Jeroen Jansen, Jennifer Jones, John Karagiannis, Nicholas Karyotakis, Arthur Kaser, Lior Katz, Seymour Katz, Leo Katz, Nirmal Kaur, Edita Kazenaite, Reena Khanna, Sunil Khurana, Joo Sung Kim, Young-Ho Kim, Sung Kook Kim, Dongwoo Kim, Jochen Klaus, Dariusz Kleczkowski, Pavel Kohout, Bartosz Korczowski, Georgios Kouklakis, Ioannis Koutroubakis, Richard Krause, Tunde Kristof, Ian Kronborg, Annette Krummenerl, Limas Kupcinskas, Jorge Laborda Molteni, David Laharie, Adi Lahat-zok, Jonghun Lee, Kang-Moon Lee, Rupert Leong, Henry Levine, Jimmy Limdi, James Lindsay, Nilesh Lodhia, Edward Loftus, Randy Longman, Pilar Lopez Serrano, Edouard Louis, Maria Helena Louzada Pereira, John Lowe, Stefan Lueth, Milan Lukas, Giovanni Maconi, Finlay Macrae, Laszlo Madi-Szabo, Uma Mahadevan-Velayos, Everson Fernando Malluta, Fazia Mana, Peter Mannon, Gerasimos Mantzaris, Ignacio Marin Jimenez, Maria Dolores Martin Arranz, Radu-Bogdan Mateescu, Felipe Mazzoleni, Agnieszka Meder, Ehud Melzer, Jessica Mertens, Konstantinos Mimidis, Brent Mitchell, Tamas Molnar, Gregory Moore, Luis Alonso Morales Garza, Reme Mountifield, Vinciane Muls, Charles Murray, Bela Nagy, Markus Neurath, Augustin Nguyen, Remo Panaccione, William Pandak, Julian Panes Diaz, Jihye Park, Luca Pastorelli, Bhaktasharan Patel, Markus Peck-Radosavljevic, Gyula Pecsi, Farhad Peerani, Javier Perez Gisbert, Martin Pesta, Robert Petryka, Raymond Phillips, Marieke Pierik, Vijayalakshmi Pratha, Vlastimil Prochazka, Istvan Racz, Graham Radford-Smith, Daniel Ramos Castañeda, Odery Ramos Júnior, Jaroslaw Regula, Jean-Marie Reimund, Bryan Robbins, Xavier Roblin, Francesca Rogai, Gerhard Rogler, Jerzy Rozciecha, David Rubin, Azalia Yuriria Ruiz Flores, Maciej Rupinski, Grazyna Rydzewska, Sumona Saha, Simone Saibeni, Agnes Salamon, Zoltan Sallo, Bruce Salzberg, Douglas Samuel, Sunil Samuel, William Sandborn, Edoardo Vincenzo Savarino, Anja Schirbel, Robert Schnabel, Stefan Schreiber, John Scott, Shahriar Sedghi, Frank Seibold, Jakob Seidelin, Ursula Seidler, Ahmad Shaban, Ira Shafran, Aasim Sheikh, Alex Sherman, Haim Shirin, Patryk Smolinski, Geun Am Song, Konstantinos Soufleris, Alexander Speight, Dirk Staessen, Andreas Stallmach, Michael Staun, Daniel Stein, Hillary Steinhart, Jonathas Stifft, David Stokesberry, Andreas Sturm, Keith Sultan, Gyorgy Szekely, Kuldeep Tagore, Hugo Tanno, Lena Thin, Syed Thiwan, Carlton Thomas, Michal Tichy, Gabor Tamas Toth, Zsolt Tulassay, Jan Ulbrych, John Valentine, Marta Varga, Eduardo Vasconcellos, Byron Vaughn, Brenda Velasco, Francisco Velazquez, Severine Vermeire, Erica Villa, Aron Vincze, Harald Vogelsang, Miroslava Volfova, Lucine Vuitton, Petr Vyhnalek, Peter Wahab, Jens Walldorf, Mattitiahu Waterman, John Weber, L. Michael Weiss, Anna Wiechowska-Kozlowska, Elise Wiesner, Thomas Witthoeft, Robert Wohlman, Barbara Wozniak-Stolarska, Bruce Yacyshyn, Byong-Duk Ye, Ziad Younes, Lígia Yukie Sassaki, Cyrla Zaltman, Stefan Zeuzem, Neurosurgery, ANS - Neurovascular Disorders, Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Peyrin-Biroulet L., Hart A., Bossuyt P., Long M., Allez M., Juillerat P., Armuzzi A., Loftus E.V., Ostad-Saffari E., Scalori A., Oh Y.S., Tole S., Chai A., Pulley J., Lacey S., Sandborn W.J., Aguilar H., Ahmad T., Akriviadis E., Aldeguer Mante X., Altorjay I., Ananthakrishnan A., Andersen V., Andreu Garcia M., Aumais G., Avni-Biron I., Axler J., Ayub K., Baert F., Bafutto M., Bamias G., Bassan I., Baum C., Beaugerie L., Behm B., Bekal P., Bennett M., Bermejo San Jose F., Bernstein C., Bettenworth D., Bhaskar S., Biancone L., Bilir B., Blaeker M., Bloom S., Bohman V., Bosques Padilla F.J., Bouhnik Y., Bouma G., Bourdages R., Brand S., Bressler B., Bruckner M., Buening C., Carbonnel F., Caves T., Chapman J., Cheon J.H., Chiba N., Chioncel C., Christodoulou D., Clodi M., Cohen A., Corazza G.R., Corlin R., Cosintino R., Cummings F., Dalal R., Danese S., De Maeyer M., De Magalhaes Francesconi C.F., De Silva A., Debinski H., Desreumaux P., Dewit O., D'Haens G., Di Felice Boratto S., Ding J.N., Dixon T., Dryden G., Du Vall G.A., Ebert M., Echarri Piudo A., Ehehalt R., Elkhashab M., Ennis C., Etzel J., Fallingborg J., Feagan B., Fejes R., Ferraz de Campos Mazo D., Ferreira de Almeida Borges V., Fischer A., Fixelle A., Fleisher M., Fowler S., Freilich B., Friedenberg K., Fries W., Fulop C., Fumery M., Fuster S., G Kiss G., Garcia Lopez S., Gassner S., Gill K., Gilletta de Saint Joseph C., Ginsburg P., Gionchetti P., Goldin E., Goldis A.-E., Gomez Jaramillo H.A., Gonciarz M., Gordon G., Green D., Grimaud J.-C., Guajardo Rodriguez R., Gurzo Z., Gutierrez A., Gyokeres T., Hahm K.B., Hanauer S., Hanson J., Harlan III W., Hasselblatt P., Hayee B., Hebuterne X., Hendy P., Heyman M., Higgins P., Hilal R., Hindryckx P., Hoentjen F., Hoffmann P., Holtkamp-Endemann F., Holtmann G., Horvat G., Howaldt S., Huber S., Ibegbu I., Iborra Colomino M.I., Irving P., Isaacs K., Jagarlamudi K., Jain R., Jankiel Miszputen S., Jansen J., Jones J., Karagiannis J., Karyotakis N., Kaser A., Katz L., Katz S., Kaur N., Kazenaite E., Khanna R., Khurana S., Kim J.S., Kim Y.-H., Kim S.K., Kim D., Klaus J., Kleczkowski D., Kohout P., Korczowski B., Kouklakis G., Koutroubakis I., Krause R., Kristof T., Kronborg I., Krummenerl A., Kupcinskas L., Laborda Molteni J., Laharie D., Lahat-zok A., Lee J., Lee K.-M., Leong R., Levine H., Limdi J., Lindsay J., Lodhia N., Loftus E., Longman R., Lopez Serrano P., Louis E., Louzada Pereira M.H., Lowe J., Lueth S., Lukas M., Maconi G., Macrae F., Madi-Szabo L., Mahadevan-Velayos U., Malluta E.F., Mana F., Mannon P., Mantzaris G., Marin Jimenez I., Martin Arranz M.D., Mateescu R.-B., Mazzoleni F., Meder A., Melzer E., Mertens J., Mimidis K., Mitchell B., Molnar T., Moore G., Morales Garza L.A., Mountifield R., Muls V., Murray C., Nagy B., Neurath M., Nguyen A., Panaccione R., Pandak W., Panes Diaz J., Park J., Pastorelli L., Patel B., Peck-Radosavljevic M., Pecsi G., Peerani F., Perez Gisbert J., Pesta M., Petryka R., Phillips R., Pierik M., Pratha V., Prochazka V., Racz I., Radford-Smith G., Ramos Castaneda D., Ramos Junior O., Regula J., Reimund J.-M., Robbins B., Roblin X., Rogai F., Rogler G., Rozciecha J., Rubin D., Ruiz Flores A.Y., Rupinski M., Rydzewska G., Saha S., Saibeni S., Salamon A., Sallo Z., Salzberg B., Samuel D., Samuel S., Sandborn W., Savarino E.V., Schirbel A., Schnabel R., Schreiber S., Scott J., Sedghi S., Seibold F., Seidelin J., Seidler U., Shaban A., Shafran I., Sheikh A., Sherman A., Shirin H., Smolinski P., Song G.A., Soufleris K., Speight A., Staessen D., Stallmach A., Staun M., Stein D., Steinhart H., Stifft J., Stokesberry D., Sturm A., Sultan K., Szekely G., Tagore K., Tanno H., Thin L., Thiwan S., Thomas C., Tichy M., Toth G.T., Tulassay Z., Ulbrych J., Valentine J., Varga M., Vasconcellos E., Vaughn B., Velasco B., Velazquez F., Vermeire S., Villa E., Vincze A., Vogelsang H., Volfova M., Vuitton L., Vyhnalek P., Wahab P., Walldorf J., Waterman M., Weber J., Weiss L.M., Wiechowska-Kozlowska A., Wiesner E., Witthoeft T., Wohlman R., Wozniak-Stolarska B., Yacyshyn B., Ye B.-D., Younes Z., Yukie Sassaki L., Zaltman C., and Zeuzem S.
- Subjects
Adult ,Male ,Ulcerative Colitis Flare ,medicine.medical_specialty ,Asia ,Adolescent ,Oceania ,Population ,Antibodies, Monoclonal, Humanized ,Injections, Subcutaneou ,Placebo ,Severity of Illness Index ,law.invention ,Middle East ,Young Adult ,Maintenance therapy ,Randomized controlled trial ,law ,Internal medicine ,Gastrointestinal Agent ,medicine ,Adverse effect ,education ,Aged ,Aged, 80 and over ,Tumor Necrosis Factor Inhibitor ,education.field_of_study ,Hepatology ,business.industry ,Remission Induction ,Gastroenterology ,Middle Aged ,South America ,medicine.disease ,Ulcerative colitis ,Europe ,Treatment Outcome ,Etrolizumab ,North America ,Colitis, Ulcerative ,Female ,business ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Human - Abstract
Summary Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission compared with placebo in patients with moderately to severely active ulcerative colitis. We aimed to evaluate the efficacy and safety of etrolizumab in patients with moderately to severely active ulcerative colitis who had been previously treated with anti-tumour necrosis factor (TNF) agents. Methods HICKORY was a multicentre, phase 3, double-blind, placebo-controlled study in adult (18–80 years) patients with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6–12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) previously treated with TNF inhibitors. Patients were recruited from 184 treatment centres across 24 countries in North America, South America, Europe, Asia, Oceania, and the Middle East. Patients needed to have an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. In cohort 1, patients received open-label etrolizumab 105 mg every 4 weeks for a 14-week induction period. In cohort 2, patients were randomly assigned (4:1) to receive subcutaneous etrolizumab 105 mg or placebo every 4 weeks for the 14-week induction phase. Patients in either cohort achieving clinical response to etrolizumab induction were eligible for the maintenance phase, in which they were randomly assigned (1:1) to receive subcutaneous etrolizumab 105 mg or placebo every 4 weeks through to week 66. Randomisation was stratified by baseline concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants (induction randomisation only), baseline disease activity, week 14 MCS remission status (maintenance randomisation only), and induction cohort (maintenance randomisation only). All patients and study site personnel were masked to treatment assignment. Primary endpoints were remission (Mayo Clinic total score [MCS] ≤2, with individual subscores of ≤1 and a rectal bleeding subscore of 0) at week 14, and remission at week 66 among patients with a clinical response (MCS with ≥3-point decrease and ≥30% reduction from baseline, plus ≥1 point decrease in rectal bleeding subscore or absolute rectal bleeding score of 0 or 1) at week 14. Efficacy was analysed using a modified intent-to-treat population. Safety analyses included all patients who received at least one dose of study drug during the induction phase. This study is registered at ClinicalTrials.gov , NCT02100696 . Findings HICKORY was conducted from May 21, 2014, to April 16, 2020, during which time 1081 patients were screened, and 609 deemed eligible for inclusion. 130 patients were included in cohort 1. In cohort 2,479 patients were randomly assigned to the induction phase (etrolizumab n=384, placebo n=95). 232 patients were randomly assigned to the maintenance phase (etrolizumab to etrolizumab n=117, etrolizumab to placebo n=115). At week 14, 71 (18·5%) of 384 patients in the etrolizumab group and six (6·3%) of 95 patients in the placebo group achieved the primary induction endpoint of remission (p=0·0033). No significant difference between etrolizumab and placebo was observed for the primary maintenance endpoint of remission at week 66 among patients with a clinical response at week 14 (27 [24·1%] of 112 vs 23 [20·2%] of 114; p=0·50). Four patients in the etrolizumab group reported treatment-related adverse events leading to treatment discontinuation. The proportion of patients reporting at least adverse event was similar between treatment groups for induction (etrolizumab 253 [66%] of 384; placebo 63 [66%] of 95) and maintenance (etrolizumab to etrolizumab 98 [88%] of 112; etrolizumab to placebo 97 [85%] of 114). The most common adverse event in both groups was ulcerative colitis flare. Most adverse events were mild or moderate. During induction, the most common serious adverse event was ulcerative colitis flare (etrolizumab ten [3%] of 384; placebo: two [2%] of 95). During maintenance, the most common serious adverse event in the etrolizumab to etrolizumab group was appendicitis (two [2%] of 112) and the most common serious adverse events in the etrolizumab to placebo group were ulcerative colitis flare (two [2%] of 114) and anaemia (two [2%] of 114). Interpretation HICKORY demonstrated that a significantly higher proportion of patients with moderately to severely active ulcerative colitis who had been previously treated with anti-TNF agent were able to achieve remission at week 14 when treated with etrolizumab compared with placebo; however, there was no significant difference between groups in remission at week 66 among patients with a clinical response at week 14. Funding F Hoffmann-La Roche.
- Published
- 2022
21. DESTRUCTION OF DILUTE ORGANIC POLLUTANTS BY GAMMA IRRADIATION.
- Author
-
Etzel, J
- Published
- 1967
22. Perioperative Multimodal Anesthetic Care Incorporating Transversus Abdominis Plane Block Is Associated With Reduced Narcotic Use in Laparoscopic Sleeve Gastrectomy.
- Author
-
Martin SP, Etzel J, Aghazarian G, Wert Y, Answine JF, and DiMarco L
- Subjects
- Bariatric Surgery adverse effects, Bariatric Surgery methods, Female, Gastrectomy adverse effects, Humans, Laparoscopy, Length of Stay, Linear Models, Male, Middle Aged, Nerve Block statistics & numerical data, Retrospective Studies, Abdominal Muscles innervation, Analgesics, Opioid administration & dosage, Gastrectomy methods, Nerve Block methods, Perioperative Care methods
- Abstract
Background: Laparoscopic sleeve gastrectomy (LSG) is the most commonly performed bariatric surgery performed in North America. As our knowledge of the importance in limiting narcotic use in postoperative patients increases, we sought to evaluate the effect of transversus abdominis plane (TAP) blocks on inpatient narcotic use in patients undergoing LSG., Methods: A retrospective review of LSG performed at a single institution by 3 bariatric surgeons was performed. All cases over a 15-month period were included, and anesthesia records were reviewed to stratify patients that received a TAP block and those that did not. Demographic, as well as surgical, outcomes were collected for all patients. Narcotic utilization, as reported in morphine equivalents (ME), was evaluated between the 2 groups., Results: 384 LSG patients were identified, of which 37 (9.6%) received a TAP block. There was no statistically significant difference in postoperative morbidity, length of stay, or readmission between groups. Median narcotic utilization in hospital days 1 and 2 in patients with TAP blocks was 49 ME (Interquartile Range (IQR) 14.5-84.5) to 82.5 ME (IQR 57.4-106) in the no-TAP group ( P < .001). After controlling for multiple demographic- and patient-related cofactors, multiple linear regression analysis demonstrated TAP block patients utilized 22.48 ME less than the no-TAP group ( P < .001) in the first 2 days of their hospitalization., Discussion: Patients that received a TAP block as a part of their perioperative anesthetic care utilized less in-hospital narcotics than those patients that did not receive a TAP block. TAP blocks should be considered as part of a multimodal pain control strategy for patients undergoing LSG.
- Published
- 2022
- Full Text
- View/download PDF
23. Expectant management of pneumothorax in intubated COVID-19 positive patients: a case series.
- Author
-
Elder C, Bawa S, Anderson D, Atkinson S, Etzel J, and Moritz T
- Subjects
- Aged, Betacoronavirus, COVID-19, Female, Humans, Male, Middle Aged, Pandemics, Pneumothorax etiology, Positive-Pressure Respiration adverse effects, SARS-CoV-2, Coronavirus Infections therapy, Pneumonia, Viral therapy, Pneumothorax therapy, Watchful Waiting
- Abstract
Background: There is an increasing amount of literature describing the pathogenesis of coronavirus disease 2019 (COVID-19) pneumonia and its associated complications. Historically, a small pneumothorax has been shown to be successfully treated without chest tube insertion, but this management has yet to be proven in COVID-19 pneumonia patients. In addition, pneumothorax in an intubated patient with high positive end-expiratory pressure (PEEP) provides additional uncertainty with pursuing non-operative management., Case Presentation: In this series we report four cases of patients with respiratory distress who tested positive for COVID-19 via nasopharyngeal swab and developed ventilator-induced pneumothoraces which were successfully managed with observation alone., Conclusions: Management of patients with COVID-19 pneumonia on positive pressure ventilation who develop small stable pneumothoraces can be safely observed without chest tube insertion.
- Published
- 2020
- Full Text
- View/download PDF
24. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
- Author
-
Koessler J, Schwarz M, Weber K, Etzel J, Koessler A, Boeck M, and Kobsar A
- Subjects
- Adult, Blood Platelets cytology, Blood Platelets metabolism, Cell Adhesion Molecules genetics, Cell Adhesion Molecules metabolism, Cell Survival genetics, Cyclic AMP metabolism, Cyclic GMP metabolism, Cyclic Nucleotide Phosphodiesterases, Type 5 genetics, Cyclic Nucleotide Phosphodiesterases, Type 5 metabolism, Female, Fibrinogen metabolism, Gene Expression Regulation, Humans, Male, Microfilament Proteins genetics, Microfilament Proteins metabolism, P-Selectin genetics, P-Selectin metabolism, Peptide Fragments pharmacology, Phosphoproteins genetics, Phosphoproteins metabolism, Phosphorylation drug effects, Platelet Activation drug effects, Platelet Aggregation drug effects, Primary Cell Culture, Protein Binding drug effects, Receptors, Purinergic P2X1 genetics, Receptors, Purinergic P2X1 metabolism, Receptors, Purinergic P2Y1 metabolism, Receptors, Purinergic P2Y12 genetics, Receptors, Purinergic P2Y12 metabolism, Vasodilator-Stimulated Phosphoprotein, Adenosine Diphosphate pharmacology, Blood Platelets drug effects, Citric Acid pharmacology, Platelet Aggregation Inhibitors pharmacology, Receptors, Purinergic P2Y1 genetics
- Abstract
Background: Platelets are important for effective hemostasis and considered to be involved in pathophysiological processes, e.g. in cardiovascular diseases. Platelets provided for research or for therapeutic use are frequently separated from citrated whole blood (WB) stored for different periods of time. Although functionally intact platelets are required, the stability of platelet integrity, e.g. adenosine diphosphate (ADP) mediated responsiveness, has never been thoroughly investigated in citrated WB under ex vivo conditions., Objectives: Platelet integrity was evaluated at different time points in citrated WB units, collected from healthy donors and stored for 5 days at ambient temperature. The analysis included the measurement of activation markers, of induced light transmission aggregometry and of purinergic receptor expression or function. Inhibitory pathways were explored by determination of basal vasodilator-stimulated phosphoprotein (VASP)-phosphorylation, intracellular cyclic nucleotide levels and the content of phosphodiesterase 5A. Fresh peripheral blood (PB) samples served as controls., Results: On day 5 of storage, thrombin receptor activating peptide-6 (TRAP-6) stimulated CD62P expression and fibrinogen binding were comparable to PB samples. ADP induced aggregation continuously decreased during storage. Purinergic receptor expression remained unchanged, whereas the P2Y1 activity progressively declined in contrast to preserved P2Y12 and P2X1 function. Inhibitory pathways were unaffected except for a slight elevation of VASP phosphorylation at Ser239 on day 5., Conclusion: After 5 days of storage in citrated WB, platelet responsiveness to TRAP-6 is sufficiently maintained. However, ADP-mediated platelet integrity is more sensitive to deterioration, especially after storage for more than 2 days. Decreasing ADP-induced aggregation is particularly caused by the impairment of the purinergic receptor P2Y1 activity. These characteristics should be considered in the use of platelets from stored citrated WB for experimental or therapeutic issues.
- Published
- 2017
- Full Text
- View/download PDF
25. Evaluation of dose-dependent effects of the proteasome inhibitor bortezomib in human platelets.
- Author
-
Koessler J, Etzel J, Weber K, Boeck M, and Kobsar A
- Subjects
- Blood Platelets metabolism, Blood Platelets physiology, Blood Proteins metabolism, Dose-Response Relationship, Drug, Female, Humans, Male, Platelet Aggregation drug effects, Ubiquitination drug effects, Young Adult, Blood Platelets drug effects, Bortezomib pharmacology, Proteasome Endopeptidase Complex metabolism, Proteasome Inhibitors pharmacology
- Abstract
Platelets express key proteins of the proteasome system and contain protein ubiquitination pathways. The functional role of the proteasome system in platelets, however, is still subject of studies. In addition to its role as anticancer drug, the potent and selective proteasome inhibitor bortezomib can be used for experimental proteasome research. Since it is mandatory to know exact dose-effect relationships, we intended to evaluate dose-dependent specific bortezomib effects on basal and on agonist-induced proteasome activitiy, on levels of poly-ubiquitinated proteins and on platelet aggregation. In washed platelets, unstimulated or stimulated with different agonists and pre-incubated with various bortezomib concentrations, the proteasome activity was determined by a fluorometric assay. The levels of poly-ubiquitinated proteins were assessed by an immunoassay kit. Platelet aggregation was measured by light transmission aggregometry in platelet-rich-plasma. Platelet agonists stimulate both, the proteasome activity and the accumulation of poly-ubiquitinated proteins in platelets. Bortezomib inhibits the basal and the agonist induced proteasome activity and increased the content of poly-ubiquitinated proteins in a concentration dependent manner. Bortezomib concentrations in the nM-range causing complete blockade of platelet proteasome activity do not affect agonist induced platelet aggregation, indicating that the level of platelet proteasome activity is not directly linked with the induction of platelet aggregation. Bortezomib in the µM-range may tamper platelet aggregation, possibly due to unspecific and toxic effects., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
26. [Value of sonography in the diagnosis and follow-up of patients with cryptogenic inflammatory bowel diseases in current practice: review of a 10-year experience in a community hospital].
- Author
-
Rubini B, Jaafar S, Gaucher H, Kissel A, Gobertier-Gasparini G, Fromaget JM, Tabary D, Muller M, and Etzel JC
- Subjects
- Diagnosis, Differential, Female, Humans, Male, Ultrasonography, Doppler, Color, Colitis, Ulcerative diagnostic imaging, Crohn Disease diagnostic imaging
- Abstract
Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the bowel that are of unknown etiology. These diseases either progress with intermittent flare-ups interrupted by periods of remission or on a chronic active progressive mode. IBDs include Crohn disease (CD) and ulcerative colitis (UC). Clinical and imaging diagnosis often is challenging, hence explaining the frequent time delay between onset of disease and initiation of therapy. Clinical evaluation is characterized by three consecutive steps: consider a diagnosis of IBD; exclude other causes of inflammatory bowel disease; differentiate CD from UC since a definitive curative surgical treatment is available for UC. US is non-invasive, widely available, easy to perform, and relatively inexpensive and thus represents a significant advance in the evaluation of these three steps. The role of US in the evaluation of patients with suspected IBD will be reviewed.
- Published
- 2001
27. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis.
- Author
-
Frieri M, Therattil J, Chavarria V, Cosachov J, Kumar NS, Wang SF, Sansone G, Etzel J, Dellevecchia D, Zitt M, Mesarina-Wicki B, and Nolop KB
- Subjects
- Adult, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Middle Aged, Mometasone Furoate, Nasal Mucosa chemistry, Nasal Mucosa cytology, Nasal Provocation Tests, Sneezing drug effects, Time Factors, Anti-Allergic Agents therapeutic use, Anti-Inflammatory Agents therapeutic use, Pregnadienediols therapeutic use, Rhinitis, Allergic, Seasonal drug therapy
- Abstract
Background: Mometasone furoate is a potent glucocorticoid that can markedly inhibit proinflammatory Th2 cytokines in vitro. An aqueous nasal spray formulation has been shown to be clinically active in reducing the symptoms of perennial and seasonal allergic rhinitis., Objective: To determine whether pretreatment with mometasone furoate 200 microg once daily decreases specific indices of early and late phase nasal inflammation compared with placebo., Methods: A randomized, double-blind, placebo-controlled crossover study was conducted using nasal provocation with ragweed antigen in 21 patients with ragweed-induced allergic rhinitis out of the ragweed season; the treatment period was 2 weeks. Symptom scores, rhinoprobe cytology, and nasal lavage fluid were collected during early and late phase periods for nasal cytokines (interleukin, 1, 4, 5, 6, and 8) and leukotriene B4 determinations using ELISA and RIA., Results: Mean nasal symptom scores and sneezing frequency were consistently lower with mometasone furoate compared with placebo. Treatment was associated with a statistically significant early phase (30-minute time point) reduction in nasal lavage histamine levels compared with placebo (14.3 versus 20.2 ng/mL, P = .02). Within-treatment comparisons suggested that mometasone furoate reduced the antigen-induced late-phase response for IL-6, IL-8, and eosinophils compared with pretreatment. There were similar, but smaller, changes seen in the placebo group for these measurements. There were no statistically significant changes following antigen challenge in IL-1, IL-4, IL-5, LTB4, or in other nasal cytology parameters., Conclusion: These results suggest that the clinical activity of mometasone furoate nasal spray in seasonal allergic rhinitis is likely due, in part, to a reduction in the levels of histamine in nasal secretions related to the early phase response, and reductions in IL-6, IL-8, and eosinophils during the late phase response.
- Published
- 1998
- Full Text
- View/download PDF
28. Impact of the development of a multidisciplinary adverse drug reaction committee.
- Author
-
Etzel JV, Brocavich JM, and Rousseau M
- Subjects
- Forms and Records Control, Humans, Program Development, Program Evaluation, United States, Adverse Drug Reaction Reporting Systems organization & administration, Professional Staff Committees organization & administration
- Abstract
A multidisciplinary Adverse Drug Reaction (ADR) committee consisting of pharmacists, nurses, and physician was formed. The committee developed an ADR Reporting Form and a 24-hour ADR Reporting Hotline to simplify ADR Reporting throughout the hospital. An ADR Newsletter and an extensive inservice education program was also implemented. Suspected ADRs are investigated by a pharmacist and presented to committee. A formal report is then forwarded to the Pharmacy and Therapeutics Committee, as well as the clinical departments within the hospital. The establishment of a formalized multidisciplinary ADR committee was successful in generating 2.1 ADR reports per 100 hospital admissions. These ADRs were reported from a variety of healthcare professionals.
- Published
- 1995
29. Dyspnea and periorbital edema following an increase in naproxen dose.
- Author
-
Briscoe-Dwyer L and Etzel JV
- Subjects
- Adult, Humans, Male, Naproxen administration & dosage, Dyspnea chemically induced, Edema chemically induced, Naproxen adverse effects, Orbital Diseases chemically induced
- Published
- 1994
- Full Text
- View/download PDF
30. Diphenhydramine-induced acute dystonia.
- Author
-
Etzel JV
- Subjects
- Acute Disease, Administration, Oral, Diphenhydramine administration & dosage, Female, Humans, Middle Aged, Diphenhydramine adverse effects, Dystonia chemically induced
- Abstract
A 45-year-old woman was administered oral and intravenous diphenhydramine 25 mg for the treatment of an allergic reaction. Within 2 minutes she rapidly developed trismus, dysarthria, tremors of the upper extremities, left-sided weakness, and diminished consciousness. She was treated with intravenous diazepam and benztropine with good response. After approximately 12 hours the patient's condition was completely resolved except for minor subjective weakness of her left extremities. Her hospital stay was uneventful, and she was discharged after 4 days after refusing rechallenge with the drug. Several cases of acute dystonic reactions secondary to antihistamines have been reported in the literature, four of which involved diphenhydramine. Such reactions may occur after short- or long-term therapy. Most patients experienced rapidly developing trismus, facial dystonia, dysarthria, and occasionally, decreases in consciousness, motor incoordination, and weakness. Because of the widespread availability of diphenhydramine and other antihistamines to the general public, awareness of this effect is of great importance.
- Published
- 1994
31. Oral azole drugs as systemic antifungal therapy.
- Author
-
Etzel JV
- Subjects
- Humans, Itraconazole administration & dosage, Mycoses drug therapy, Itraconazole therapeutic use
- Published
- 1994
32. Endocrine complications associated with human immunodeficiency virus infection.
- Author
-
Etzel JV, Brocavich JM, and Torre M
- Subjects
- Adrenal Gland Diseases etiology, Anti-Infective Agents adverse effects, HIV Infections drug therapy, Humans, Hypoaldosteronism etiology, Male, Pancreatic Diseases etiology, Parathyroid Diseases etiology, Testicular Diseases etiology, Thyroid Diseases etiology, Endocrine System Diseases etiology, HIV Infections complications
- Abstract
The causes and management of endocrine disorders associated with human immunodeficiency virus (HIV) infection are reviewed. Endocrine disorders observed in HIV-positive patients include adrenal abnormalities, hyporeninemic hypoaldosteronism, pituitary insufficiency, pancreatic abnormalities, thyroid and parathyroid disorders, and testicular abnormalities. Opportunistic pathogens implicated in these disorders include cytomegalovirus, Cryptococcus, Toxoplasma, mycobacteria, Candida, and Aspergillus. Neoplasma such as Kaposi's sarcoma and lymphoma can also cause endocrine abnormalities. Several drugs used in patients with the acquired immunodeficiency syndrome (AIDS) are associated with the development of endocrine disorders. These drugs include ketoconazole, itraconazole, rifampin, vidarabine, pentamidine, trimethoprim-sulfamethoxazole, didanosine, and ganciclovir. Severe patient debilitation can contribute to the development of endocrine abnormalities. Monitoring of adrenal gland function may be prudent in HIV-infected patients who have nonspecific symptoms of adrenal insufficiency. If adrenal insufficiency is diagnosed, replacement therapy with oral hydrocortisone is required. Administration of fludrocortisone can rapidly alleviate the signs and symptoms of hyporeninemic hypoaldosteronism. Fluid restriction is the first step in managing the pituitary abnormality known as the syndrome of inappropriate secretion of antidiuretic hormone. Drug-induced endocrine abnormalities often resolve after withdrawal of the offending agent. Endocrine complications in HIV-infected patients may be caused by infection, malignancy, or drugs. Adjusting or instituting drug therapy may be necessary to control symptomatic endocrine abnormalities.
- Published
- 1992
33. Topical uses of testosterone.
- Author
-
Etzel JV, Lin AY, and Barber PG
- Subjects
- Administration, Topical, Female, Humans, Male, Ointments, Testosterone administration & dosage, Hypogonadism drug therapy, Penile Diseases drug therapy, Testosterone therapeutic use, Vulvar Diseases drug therapy
- Published
- 1991
34. [Dysplasia of the lymphatic system in Noonan's syndrome (author's transl)].
- Author
-
Juncker P, Hoeffel JC, Remy J, and Etzel JC
- Subjects
- Child, Female, Humans, Lymphography, Male, Lymphatic System abnormalities, Noonan Syndrome diagnostic imaging
- Published
- 1979
35. [Direct image of hepatic lipoma].
- Author
-
Hoeffel JC, Etzel JC, Drouin P, and Boissel P
- Subjects
- Female, Humans, Lipoma pathology, Liver Neoplasms pathology, Middle Aged, Radiography, Lipoma diagnostic imaging, Liver Neoplasms diagnostic imaging
- Abstract
The authors report an unusual case of hepatic lipoma the originality of which consists in the demonstration on the radiograph of a large translucid image in the hepatic area suggestive of a lipoma.
- Published
- 1977
36. [Radiological appearances of angioblastosarcomas: A report on one case and review of the published literature (author's transl)].
- Author
-
Etzel JC, Froehlich C, and Hoeffel JC
- Subjects
- Adolescent, Bone Neoplasms diagnosis, Fibula diagnostic imaging, Hemangiosarcoma diagnosis, Humans, Lung Neoplasms secondary, Male, Radiography, Tibia diagnostic imaging, Bone Neoplasms diagnostic imaging, Hemangiosarcoma diagnostic imaging
- Abstract
A 16-year-old adolescent with metaphysial osteolysis of the proximal end of the fibula was found to have radiological and histological signs suggesting an aneurysmal cyst. Repeated radiological examinations demonstrated local signs of malignancy, followed by the appearance of pulmonary metastases. At the same time, however, histological examination of various tissue samples gave contradictory results leading to a diagnosis of angioblastosarcoma. This is a rare tumor, and the authors describe its principal radiological characteristics and its progression as reported in cases published in the literature.
- Published
- 1980
37. Microbial decomposition of pentachlorophenol.
- Author
-
Kirsch EJ and Etzel JE
- Subjects
- Bacteriological Techniques, Biodegradation, Environmental, Culture Media, Pentachlorophenol metabolism, Herbicides metabolism, Phenols metabolism
- Published
- 1973
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.